# For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival was 12.4 months with gedatolisib + palbociclib + fulvestrant.

*biotech · news · 2025-12-11 · The Manila Times*

## Key points

- Gedatolisib triplet showed a median PFS of 16.6 months in US, Canada, Western Europe, and Asia Pacific.
- Patients progressing >18 months on prior therapy had median PFS of 12.4 months with gedatolisib triplet.
- No clinically relevant hyperglycemia or dose reductions due to hyperglycemia were reported with gedatolisib.
- Stomatitis from gedatolisib was generally controlled, resolving to a lower grade within two weeks.

**Companies:** Celcuity Inc.
**Countries:** United States, Canada, Western Europe, Australia

[Read the full story on The Manila Times](https://www.manilatimes.net/2025/12/12/tmt-newswire/globenewswire/celcuity-presents-updated-results-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium/2242022)

---

Canonical: https://newsio.io/n/f3157c24-4736-467d-a1ad-5d24bfed4cbc/for-patients-whose-time-to-progression-on-immediate-prior-therapy-was-18-months
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works